Dark Forest Capital Management LP Makes New Investment in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Dark Forest Capital Management LP bought a new stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 38,126 shares of the company’s stock, valued at approximately $88,000. Dark Forest Capital Management LP owned approximately 0.05% of Ventyx Biosciences at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. Norden Group LLC purchased a new position in Ventyx Biosciences in the 1st quarter valued at $59,000. China Universal Asset Management Co. Ltd. raised its position in shares of Ventyx Biosciences by 66.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 11,385 shares of the company’s stock valued at $63,000 after buying an additional 4,553 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Ventyx Biosciences in the first quarter valued at about $72,000. SG Americas Securities LLC purchased a new position in shares of Ventyx Biosciences in the second quarter worth about $32,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Ventyx Biosciences during the second quarter worth about $58,000. 97.88% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on VTYX shares. Wells Fargo & Company decreased their target price on shares of Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. Oppenheimer lowered their price objective on Ventyx Biosciences from $12.00 to $10.00 and set an “outperform” rating on the stock in a research note on Thursday, June 6th. HC Wainwright reaffirmed a “neutral” rating and issued a $6.00 target price on shares of Ventyx Biosciences in a research note on Monday, September 23rd. Finally, Canaccord Genuity Group reduced their price target on Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating on the stock in a report on Monday, August 12th. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Ventyx Biosciences has an average rating of “Moderate Buy” and a consensus target price of $8.29.

Ventyx Biosciences Trading Down 5.6 %

NASDAQ VTYX opened at $2.18 on Tuesday. The stock has a fifty day simple moving average of $2.24 and a 200-day simple moving average of $3.52. The stock has a market cap of $154.06 million, a PE ratio of -0.71 and a beta of 0.37. Ventyx Biosciences, Inc. has a twelve month low of $1.79 and a twelve month high of $34.49.

Ventyx Biosciences (NASDAQ:VTYX) last announced its earnings results on Thursday, August 8th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.12. Research analysts predict that Ventyx Biosciences, Inc. will post -2.14 EPS for the current year.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.